Visiopharm

Visiopharm specializes in AI-driven precision pathology software, enhancing research and diagnostics through advanced tissue analysis solutions that improve patient treatment strategies. Founded in 2001 and based in Denmark, Visiopharm develops precision pathology software that aids in research and diagnostics. The company has undergone no significant pivots and operates independently. CEO Michael Pathology leads the company, which has engaged in 2 deals, the most recent being in May 2015 when Visiopharm raised financing from NorthCap Partners.

Visiopharm is a prominent provider of AI-driven precision pathology software designed for research and diagnostic applications. The company’s primary offerings include the Discovery platform and Phenoplex™, which integrate advanced artificial intelligence with over 20 years of domain expertise in pathology. These platforms allow users, including pathologists and research scientists, to perform nuanced tissue analysis, facilitating the development of next-generation therapies and improving patient stratification for treatment. Visiopharm's software has been validated for various applications, including the quantification of biomarkers in clinical research and diagnostics across multiple disease areas such as oncology and liver diseases.

The company's customer base spans numerous geographical markets, including North America and Europe, where they serve academic institutions, pharmaceutical companies, and research laboratories. In 2024, Visiopharm reported a revenue of USD 17,199. 90 and an EBITDA of USD -348. Visiopharm plans to enhance its product offerings with upcoming releases of new software features designed to improve usability and functionality, although specific launch dates have not been disclosed.

The company aims to expand into new markets, particularly in Asia and Australia, by 2025. The financing raised in May 2015 will support these initiatives, facilitating further development of their platforms and enabling entry into these targeted regions.